Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Felix Stader"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 5, Pp 781-794 (2024)
Abstract There is growing interest in the use of long‐acting (LA) injectable drugs to improve treatment adherence. However, their long elimination half‐life complicates the conduct of clinical trials. Physiologically‐based pharmacokinetic (PBPK
Externí odkaz:
https://doaj.org/article/cc043f465e374806a90b5d4baad0c733
Publikováno v:
Pharmaceutics, Vol 16, Iss 10, p 1284 (2024)
Background/Objectives: Plasma levels of 4β-hydroxycholesterol (4β-OHC), a CYP3A-specific metabolite of cholesterol, are elevated after administration of CYP3A inducers like rifampicin and carbamazepine. To simulate such plasma 4β-OHC increase, we
Externí odkaz:
https://doaj.org/article/196f7ff56933489ebead894d0428330a
Autor:
Felix Stader, Cong Liu, Abdallah Derbalah, Hiroshi Momiji, Xian Pan, Iain Gardner, Masoud Jamei, Armin Sepp
Publikováno v:
Antibodies, Vol 13, Iss 3, p 70 (2024)
The bioavailability of a monoclonal antibody (mAb) or another therapeutic protein after subcutaneous (SC) dosing is challenging to predict from first principles, even if the impact of injection site physiology and drug properties on mAb bioavailabili
Externí odkaz:
https://doaj.org/article/0318d20ff39a45c19a6b62c7a4b24ef2
Autor:
Weize Huang, Felix Stader, Phyllis Chan, Colby S. Shemesh, Yuan Chen, Katherine L. Gill, Hannah M. Jones, Linzhong Li, Gianluca Rossato, Benjamin Wu, Jin Y. Jin, Pascal Chanu
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: Atezolizumab has been studied in multiple indications for both pediatric and adult patient populations. Generally, clinical studies enrolling pediatric patients may not collect sufficient pharmacokinetic data to characterize the drug expo
Externí odkaz:
https://doaj.org/article/3faa387e1cec491bb32e60f6076ebfaa
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 7, Pp 444-459 (2019)
Physiologically‐based pharmacokinetic (PBPK) models are useful tools to predict clinical scenarios for special populations for whom there are high hurdles to conduct clinical trials such as children or the elderly. However, the coding of a PBPK mod
Externí odkaz:
https://doaj.org/article/cdfc76a8fba14843811c51cf20e0d96a
Publikováno v:
Clinical Infectious Diseases. 76:1225-1236
Background Long-acting (LA) intramuscular cabotegravir and rilpivirine are prone to drug-drug interactions (DDI). However, given the long dosing interval, the conduct of clinical DDIs studies with LA antiretrovirals is challenging. We performed virtu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b18923fdb1c07bf5a5b137522d96c66a
https://doi.org/10.1093/cid/ciac901
https://doi.org/10.1093/cid/ciac901
Publikováno v:
Xenobiotica. 52:840-854
The past two decades have seen diversification of drug development pipelines and approvals from traditional small molecule therapies to alternative modalities including monoclonal antibodies, engineered proteins, antibody drug conjugates (ADCs), olig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a01fffd9eedd1077e045f40adeb1542e
https://doi.org/10.1080/00498254.2022.2133649
https://doi.org/10.1080/00498254.2022.2133649
Autor:
Jill Barber, Zubida M. Al-Majdoub, Narciso Couto, Martyn Howard, Yasmine Elmorsi, Daniel Scotcher, Naved Alizai, Saskia de Wildt, Felix Stader, Armin Sepp, Amin Rostami-Hodjegan, Brahim Achour
Publikováno v:
European Journal of Pharmaceutical Sciences, 182
Contains fulltext : 290153.pdf (Publisher’s version ) (Open Access)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b6187b781fa739e84153ffb650bd54d
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/290153
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/290153
Publikováno v:
Clinical pharmacokinetics.
Obese individuals are often underrepresented in clinical trials, leading to a lack of dosing guidance.This study aimed to investigate which physiological parameters and drug properties determine drug disposition changes in obese using our physiologic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea7b8b98c15dbad62982a4669ce028eb
https://pubmed.ncbi.nlm.nih.gov/36571702
https://pubmed.ncbi.nlm.nih.gov/36571702
Publikováno v:
Clinical Pharmacology and Therapeutics
Bictegravir is equally metabolized by cytochrome P450 (CYP)3A and uridine diphosphate‐glucuronosyltransferase (UGT)1A1. Drug–drug interaction (DDI) studies were only conducted for strong inhibitors and inducers, leading to some uncertainty whethe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2649a691708693b567cf91c3f4ddca6
https://doi.org/10.1002/cpt.2221
https://doi.org/10.1002/cpt.2221